Partnerships
Advancing Antiviral Innovation
Partnerships drive our mission to revolutionize the treatment of infectious diseases.
We look to collaborate with leading biopharmaceutical companies, academic institutions, and global health organizations to accelerate the development of transformative therapies.
Whether leveraging our innovative science, existing therapeutics, or bespoke drug discovery capabilities, we are committed to building impactful alliances.
Partner with Us
Existing Targets
Collaborate with us to explore and develop therapies for validated, novel targets such as RdRp Thumb-1, a highly conserved and cryptic site that enables broad-spectrum antiviral activity. Leverage our expertise to accelerate drug development pipelines.
Existing Therapeutics
Tap into our portfolio of innovative antiviral candidates, including MDL-001, a first-in-class broad-spectrum antiviral. Partner with us to out-license programs or co-develop assets ready for clinical advancement.
Antiviral Discovery Under Mandate
Collaborate on customized drug discovery programs to address specific therapeutic needs. By combining your expertise with our advanced medicinal chemistry and virology platforms, we can co-create novel therapies tailored to unmet medical challenges.
Contact
Revolutionizing Antiviral Treatment
learn more
Science
Explore the Science
Learn more about the groundbreaking discovery of RdRp Thumb-1 and the innovative science driving our mission to transform global health.
Pipeline